[1]邢双双,赵晓茜,胡雁,等.145例恶性淋巴细胞增殖性疾病患者行90 min静脉快速输注奥妥珠单抗输液反应的观察与护理[J].军事护理,2023,40(10):114-116.[doi:10.3969/j.issn.2097-1826.2023.10.027]
　XING Shuangshuang,ZHAO Xiaoqian,HU Yan,et al.Observation and Nursing of 145 Patients with Malignant Lymphoproliferative Disease Receiving 90 min Intravenous Infusion of Obinutuzumab Infusion[J].Nursing Journal Of Chinese People's Laberation Army,2023,40(10):114-116.[doi:10.3969/j.issn.2097-1826.2023.10.027]
点击复制

145例恶性淋巴细胞增殖性疾病患者行90 min静脉快速输注奥妥珠单抗输液反应的观察与护理
分享到：

《军事护理》[ISSN:2097-1826/CN:31-3186/R]

卷:
40
期数:
2023年10期
页码:
114-116
栏目:
专科护理
出版日期:
2023-10-15

文章信息/Info

Title:
Observation and Nursing of 145 Patients with Malignant Lymphoproliferative Disease Receiving 90 min Intravenous Infusion of Obinutuzumab Infusion
文章编号:
2097-1826(2023)10-0114-03
作者:
邢双双1; 赵晓茜1; 胡雁1; 濮益琴1; 张飞彦1; 顾则娟2; 杜长艳1; 徐颖1;  孙进宁1; 李建勇1; 徐卫1; 范磊1
(1.南京医科大学第一附属医院/江苏省人民医院 血液科,江苏 南京,210029; 2.南京医科大学第一附属医院/江苏省人民医院 护理部)
Author(s):
XING Shuangshuang1; ZHAO Xiaoqian1; HU Yan1; PU Yiqin1; ZHANG Feiyan1; GU Zejuan2; DU Changyan1; XU Ying1; SUN Jinning1; LI Jianyong1; XU Wei1; F
(1.Department of Hematology,The First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People's Hospital,Nanjing 210029,Jiangsu Province,China; 2.Department of Nursing,The First Affiliated Hospital of Nanjing Medical University/Jiangsu Provincial People's Hospital)
关键词:
奥妥珠单抗;  快速输注法;  静脉输液反应;  护理
Keywords:
obinutuzumab;  rapid infusion method;  infusion-related reaction;  nursing
分类号:
R473.55
DOI:
10.3969/j.issn.2097-1826.2023.10.027
文献标志码:
A
摘要:
从奥妥珠单抗静脉输液反应的预防、奥妥珠单抗静脉输液反应的处理等方面总结145例恶性淋巴细胞增殖性疾病患者行90 min静脉快速输注奥妥珠单抗静脉输液反应的护理经验。所有患者于治疗的第1周期均采用奥妥珠单抗标准输注方案,针对第1周期未发生≥3级输液反应的患者,从第2周期开始采用90 min奥妥珠单抗快速输注方案。145例患者共接受730次奥妥珠单抗治疗,其中行快速输注方案583次。在标准输注过程中,共17例(11.72%)患者发生输液反应,其中3级输液反应3例(2.07%)。在快速输注过程中,仅1例(0.70%)患者发生1级输液反应。该方法具有可行性和便利性,建议加强奥妥珠单抗用药相关的护士培训,以便临床推广应用。
Abstract:
To summarize the nursing experience of 145 patients with malignant lymphoproliferative disease who received 90-minute intravenous infusion of obinutuzumab from the aspects of the prevention and treatment of obinutuzumab intravenous infusion reaction.All patients were treated with obinutuzumab standard infusion regimen in the first cycle of treatment.For patients who did not experience ≥ grade 3 infusion reactions in the first cycle,a 90-minute rapid infusion regimen of obinutuzumab was used from the second cycle.A total of 145 patients received 730 infusions of obinutuzumab,including 583 infusions of rapid infusion.During the standard infusion,a total of 17 patients(11.72%)had infusion reactions,including 3 patients(2.07%)with grade 3 infusion reactions.During the rapid infusion,only 1 patient(0.70%)had grade 1 infusion reaction.This method is feasible and convenient.It is suggested to strengthen the nurse training of obinutuzumab medication so as to promote it in the clinical context.

参考文献/References:

[1] 中国临床肿瘤学会(CSCO)淋巴瘤专家委员会.奥妥珠单抗临床用药指导原则中国专家共识(2021年版)[J].白血病·淋巴瘤,2021,30(10):581-587.
[2] 尹桂森,刘中秋,薛淑一,等.基于openFDA数据库对奥妥珠单抗不良事件信号的挖掘与分析[J].药物流行病学杂志,2022,31(11):744-749.
[3] Food and Drug Administration.GAZYVA(obinutuzumab)injection,for intravenous infusion[M].South San Francisco,CA: Genentech,Inc,2016,20.
[4] ALBENDEA M C,BUCHHOLZ T A,IZUTSU K,et al.Obinutuzumab short-duration infusion(SDI)in previously untreated advanced follicular lymphoma:results from the end of induction analysis of the phase Ⅳ gazelle study[J/OL].[2021-01-20].https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.7545.DOI: 10.1200/JCO.2021.39.15_suppl.7545.
[5] OHMACHI K,ANDO K,KINOSHITA T,et al.Safety,tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase Ⅱ GATS study[J].Jpn J Clin Oncol,2018,48(8):736-742.
[6] 中国老年保健协会淋巴瘤专业委员会,中华医学会血液学分会.利妥昔单抗静脉快速输注中国专家共识(2020年版)[J].白血病·淋巴瘤,2021,30(1):1-4.
[7] 中国国家药品监督管理局.奥妥珠单抗注射液说明书[EB/OL].[2021-06-01].https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=3cb63c46a31a1c1e574e1fa2fa2aba58.
[8] ILLIDGE T,KLEIN C,SEHN L H,et al.Obinutuzumab in hematologic malignancies:lessons learned to date[J].Cancer Treat Rev,2015,41(9):784-792.
[9] TOBINAI K,KLEIN C,OYA N,et al.A review of obinutuzumab(GA101),a novel type Ⅱ anti-CD20 monoclonal antibody,for the treatment of patients with B-cell malignancies[J].Adv Ther,2017,34(2):324-356.
[10]VOGEL W H.Infusion reactions:diagnosis,assessment,and management[J].Clin J Oncol Nurs,2010,14(2):E10-E21.
[11]张帆,周文琴.《ESMO临床实践指南:系统性抗癌治疗输液反应的管理(2017版)解读》[J].护理学杂志,2018,33(17):15-19.
[12]BYRD J C,WASELENKO J K,MANEATIS T J,et al.Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance[J].J Clin Oncol,1999,17(3):791-795.
[13]胡娟,彭艳妮,缪英霞,等.调整输注方法减轻弥漫大B细胞淋巴瘤患者首次使用利妥昔单抗致不良反应的效果观察[J].解放军护理杂志,2020,37(10):88-90.

备注/Memo

备注/Memo:
【收稿日期】2023-02-14【修回日期】2023-08-29
【基金项目】江苏省医学创新团队项目(CXTDA2017019); 江苏省人民医院临床能力提升护理项目(JSPH-NC-2021-09)
【作者简介】邢双双,硕士,主管护师,电话:025-68305379
【通信作者】赵晓茜,电话:025-68306974
更新日期/Last Update: 2023-10-15